Drug Profile
Daprodustat - GSK
Alternative Names: 1278863; Duvroq; GSK-1278863; GSK-1278863A; JesduvroqLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Acetic acids; Amides; Anti-ischaemics; Antianaemics; Cyclohexanes; Foot disorder therapies; Ketones; Pyrimidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Anaemia
- Discontinued Diabetic foot ulcer; Perioperative ischaemia; Peripheral arterial disorders; Tendon injuries
Most Recent Events
- 06 Sep 2023 Phase-III clinical trials in Anaemia (In infants, In children, In adolescents) in United Kingdom, USA, Turkey, Poland, Spain, Netherlands, Japan, South Korea, Italy, Germany, France, Canada, Belgium, Austria and Argentina (PO) (NCT05682326)
- 22 Jul 2023 CHMP recommends approval of Daprodustat for Anaemia in EU
- 12 Jul 2023 Regulatory submission withdrawn for Anaemia (In adults) in European Union (PO)